1. Home
  2. MVST vs FENC Comparison

MVST vs FENC Comparison

Compare MVST & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Microvast Holdings Inc.

MVST

Microvast Holdings Inc.

HOLD

Current Price

$2.95

Market Cap

848.0M

Sector

Miscellaneous

ML Signal

HOLD

Logo Fennec Pharmaceuticals Inc.

FENC

Fennec Pharmaceuticals Inc.

HOLD

Current Price

$7.58

Market Cap

258.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MVST
FENC
Founded
2006
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
848.0M
258.5M
IPO Year
N/A
2001

Fundamental Metrics

Financial Performance
Metric
MVST
FENC
Price
$2.95
$7.58
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$6.00
$13.50
AVG Volume (30 Days)
4.7M
154.3K
Earning Date
11-10-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$444,504,000.00
$38,790,000.00
Revenue This Year
$24.14
N/A
Revenue Next Year
$28.49
$75.22
P/E Ratio
N/A
N/A
Revenue Growth
19.82
N/A
52 Week Low
$1.09
$4.68
52 Week High
$7.12
$9.92

Technical Indicators

Market Signals
Indicator
MVST
FENC
Relative Strength Index (RSI) 33.69 45.98
Support Level $3.28 $7.50
Resistance Level $3.03 $8.00
Average True Range (ATR) 0.21 0.29
MACD -0.01 0.02
Stochastic Oscillator 14.35 43.08

Price Performance

Historical Comparison
MVST
FENC

About MVST Microvast Holdings Inc.

Microvast Holdings Inc is a technology innovator that designs, develops, and manufactures lithium-ion battery solutions. It is renowned for its cutting-edge cell technology and its vertical integration capabilities which extends from core battery chemistry to battery packs.

About FENC Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Share on Social Networks: